AU2002222932A1 - N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists - Google Patents
N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonistsInfo
- Publication number
- AU2002222932A1 AU2002222932A1 AU2002222932A AU2293202A AU2002222932A1 AU 2002222932 A1 AU2002222932 A1 AU 2002222932A1 AU 2002222932 A AU2002222932 A AU 2002222932A AU 2293202 A AU2293202 A AU 2293202A AU 2002222932 A1 AU2002222932 A1 AU 2002222932A1
- Authority
- AU
- Australia
- Prior art keywords
- cyclylamine
- hydroxyethylamines
- sulfonylaryl
- beta
- receptor agonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21858900P | 2000-07-17 | 2000-07-17 | |
| US60218589 | 2000-07-17 | ||
| PCT/US2001/022379 WO2002006274A1 (en) | 2000-07-17 | 2001-07-16 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002222932A1 true AU2002222932A1 (en) | 2002-01-30 |
Family
ID=22815690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002222932A Abandoned AU2002222932A1 (en) | 2000-07-17 | 2001-07-16 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US6444685B1 (en) |
| AU (1) | AU2002222932A1 (en) |
| WO (1) | WO2002006274A1 (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2798126B1 (en) * | 1999-09-08 | 2001-10-19 | Sanofi Synthelabo | HETEROARYLOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| DE60033964T2 (en) * | 1999-12-17 | 2007-11-29 | Sanofi-Aventis | PHENOXYPROPANOLAMINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE |
| US6498170B2 (en) | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
| US6525202B2 (en) * | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6410734B1 (en) * | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| EP1236723A1 (en) | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
| US6797707B2 (en) | 2002-03-29 | 2004-09-28 | University Of Florida | Antagonists of RF-amide neuropeptides |
| EP1927594A1 (en) | 2003-01-14 | 2008-06-04 | Arena Pharmaceuticals, Inc. | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| CN102558155A (en) * | 2003-01-14 | 2012-07-11 | 阿伦纳药品公司 | Aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of diseases related thereto, such as diabetes and hyperglycemia |
| AR045047A1 (en) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES |
| US7781457B2 (en) * | 2003-09-23 | 2010-08-24 | Merck Sharp & Dohme Corp. | Isoquinolinone potassium channel inhibitors |
| ZA200803226B (en) * | 2005-10-13 | 2009-11-25 | Orchid Res Lab Ltd | Heterocyclic Compounds as Pstat3/IL-6 Inhibitors |
| US20100099676A1 (en) * | 2006-11-02 | 2010-04-22 | Shionogi & Co., Ltd. | Sulfonylurea derivative capable of selectively inhibiting mmp-13 |
| GB0815782D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| GB0815784D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| US9067947B2 (en) * | 2009-01-16 | 2015-06-30 | Universal Display Corporation | Organic electroluminescent materials and devices |
| PH12013500221A1 (en) | 2010-08-03 | 2017-08-23 | Altherx Inc | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| EA201390421A1 (en) | 2010-09-22 | 2013-09-30 | Арена Фармасьютикалз, Инк. | GPR119 RECEPTOR MODULATORS AND TREATMENT OF RELATED DISORDERS |
| RU2623878C2 (en) | 2010-12-10 | 2017-06-29 | Броади Хэлс Сайенсис, Эл Эл Си | Jasmonate application for bladder function disorders treatment |
| CA2969405A1 (en) | 2014-12-03 | 2016-06-09 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| EP4445956A3 (en) | 2015-01-06 | 2024-12-04 | Arena Pharmaceuticals, Inc. | Compound for use in treating conditions related to the s1p1 receptor |
| PL3310760T3 (en) | 2015-06-22 | 2023-03-06 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders |
| IL310527A (en) | 2015-10-23 | 2024-03-01 | B3Ar Therapeutics Inc | Solabegron zwitterion and uses thereof |
| CN110520124A (en) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | For treating the Compounds and methods for of primary biliary cholangitis |
| JP2021042126A (en) * | 2017-12-27 | 2021-03-18 | 佐藤製薬株式会社 | Aryloxy compound |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143928A (en) | 1990-03-27 | 1992-09-01 | Warner-Lambert Company | 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents |
| EP0449261A3 (en) | 1990-03-29 | 1992-02-26 | Kabushiki Kaisha Toshiba | Resin composition for an optical disc and an optical disc using it |
| US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| TW363959B (en) | 1994-03-23 | 1999-07-11 | Sankyo Co | Thiazolidine and oxazolidine derivatives, their preparation and their medical use |
| US5561142A (en) | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
| US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
| US5789402A (en) | 1995-01-17 | 1998-08-04 | Eli Lilly Company | Compounds having effects on serotonin-related systems |
| US5741789A (en) | 1995-01-17 | 1998-04-21 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US5614523A (en) | 1995-01-17 | 1997-03-25 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| AU715216B2 (en) | 1995-10-26 | 2000-01-20 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same |
| RU2250105C2 (en) * | 1997-11-14 | 2005-04-20 | Дж.Д.Сёрл ЛЛС | Aromatic sulfonohydroxamic acid as metalloprotease inhibitor |
| FR2780057B1 (en) | 1998-06-18 | 2002-09-13 | Sanofi Sa | PHENOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR2798126B1 (en) | 1999-09-08 | 2001-10-19 | Sanofi Synthelabo | HETEROARYLOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| DE60033964T2 (en) | 1999-12-17 | 2007-11-29 | Sanofi-Aventis | PHENOXYPROPANOLAMINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE |
| FR2802533B1 (en) | 1999-12-17 | 2002-02-15 | Sanofi Synthelabo | PHENOXYPROPANOLAMINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
-
2001
- 2001-07-12 US US09/904,114 patent/US6444685B1/en not_active Expired - Fee Related
- 2001-07-16 WO PCT/US2001/022379 patent/WO2002006274A1/en not_active Ceased
- 2001-07-16 AU AU2002222932A patent/AU2002222932A1/en not_active Abandoned
-
2002
- 2002-07-25 US US10/205,019 patent/US6743787B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6743787B2 (en) | 2004-06-01 |
| US20020028797A1 (en) | 2002-03-07 |
| US6444685B1 (en) | 2002-09-03 |
| WO2002006274A1 (en) | 2002-01-24 |
| US20030027795A1 (en) | 2003-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002222932A1 (en) | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | |
| AU2001280568A1 (en) | Heterocyclic beta-3 adrenergic receptor agonists | |
| AU2002222929A1 (en) | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | |
| AU2002222930A1 (en) | Cyclic amine phenyl beta-3 adrenergic receptor agonists | |
| IL154911A0 (en) | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists | |
| ATE430124T1 (en) | ARYLANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | |
| AU2001275946A1 (en) | Substituted 2-(s)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(r)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine beta-3 adrenergic receptor agonists | |
| AU2001273728A1 (en) | Arrangement for connecting planar components | |
| AU2002210782A1 (en) | Amide derivatives as nmda receptor antagonists | |
| AU2001273515A1 (en) | Azolidines as beta-3 adrenergic receptor agonists | |
| AU2003243637A1 (en) | Cannabinoid receptor agonists | |
| AU2001273508A1 (en) | Heterocyclic beta-3 adrenergic receptor agonists | |
| AU2001273542A1 (en) | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists | |
| AU2001246934A1 (en) | Agonist antibodies | |
| AU2001286409A1 (en) | N-methyl-d-aspartate receptor antagonists | |
| AU2003248356A1 (en) | Beta3-adrenergic receptor agonists | |
| AU1100300A (en) | Piperidyloxadiazoles as dopamine receptor antagonists | |
| AU2001248998A1 (en) | Method for the preparation of (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1- naphthalenemethanamine (terbinafine) | |
| AU2001273501A1 (en) | Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists | |
| AU2001230594A1 (en) | Novel scavenger receptors | |
| AU2001273516A1 (en) | Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists | |
| AU2001223882A1 (en) | Receptor | |
| AUPQ563400A0 (en) | Novel receptor | |
| AU2002346030A1 (en) | Novel receptors | |
| PL372467A1 (en) | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists |